See the latest report "Drug Class Review: Agents for Overactive Bladder"
This publication is provided for historical reference only and the information may be out of date.
Drug Class Review on Agents for Overactive Bladder
Drug Class Reviews
Authors
Marian S McDonagh, PharmD, Dana Selover, MD, MPH, John Santa, MD, and Sarah Lopez, BA.Affiliations
Overactive bladder syndrome (OAB) is defined by the International Continence Society (ICS) as a medical condition referring to the urinary symptoms of frequency and urgency, with or without urge incontinence, when appearing in the absence of local pathological factors. Nocturia is also commonly present. The purpose of this review is to compare the efficacy, effectiveness, and adverse effects of the pharmacological treatments for OAB. Pharmacological treatment includes darifenacin, flavoxate hydrochloride, hyoscyamine, oxybutynin chloride, tolterodine tartrate, trospium chloride, scopolamine transdermal, and solifenacin succinate.
The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.